Cargando…
High dose Chemotherapy and Autologous Stem Cell Transplantation for Poor Risk and Recurrent Non-Hodgkin’s Lymphoma: A Single-Center Experience of 50 Patients
BACKGROUND: The long-term survival of patients with non-Hodgkin’s lymphoma after conventional chemotherapy is about 35%, with the remaining 65% of patients tending to be refractory or experience relapse. As such, primary refractory patients responding to salvage chemotherapy, and sensitive relapsed...
Autores principales: | Shim, Byoung Yong, Lee, Myoung A, Byun, Jae-Ho, Roh, Sang Young, Song, Chi-Won, Park, Jin-No, Lee, Jong Wook, Min, Woo Sung, Hong, Young Seon, Kim, Chun Choo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531588/ https://www.ncbi.nlm.nih.gov/pubmed/15366643 http://dx.doi.org/10.3904/kjim.2004.19.2.114 |
Ejemplares similares
-
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016) -
Hodgkin’s lymphoma: post- autologous transplantation consolidation therapy
por: Merli, Francesco, et al.
Publicado: (2020) -
High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience
por: Chang, Hyun, et al.
Publicado: (2006) -
Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation
por: Radford, J, et al.
Publicado: (2017) -
Autologous hematopoietic stem cell transplantation in classical Hodgkin's lymphoma
por: Cortez, Afonso José Pereira, et al.
Publicado: (2011)